Evidence map›Paper›PMID 30961539›Full record

SynthesisBMC gastroenterology2019

Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: a systematic review and meta-analysis.

Ke Pu, Yuping Wang, Suyang Bai, Hui Wei, Yongning Zhou, Jiangao Fan, Liang Qiao

Registry-linked trialOpen access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMC gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04574557 (Hepatic Micro RNA Expression In Non Alcoholic Fatty Liver Disease), which is not on this map. Cited by 101 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
101citing papers in PubMed, 8 pooled it
15.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04574557 unknown statusnot on this mapstarted 2020, after this paper: background citation

Hepatic Micro RNA Expression In Non Alcoholic Fatty Liver Disease

TypeobservationalSponsorAssiut UniversityRan2020 to 2022Enrolled80ConditionsNon-Alcoholic Fatty Liver DiseaseArmsmicro RNA
3 · Its place in the literature

Who cites it

101 citing papers in PubMed, 8 syntheses or guidelines pooled it, 186 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Guideline
  4. Guideline
  5. Pooled it
  6. Guideline
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

41 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Ke PuDepartment of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou, China.
Yuping WangDepartment of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou, China.
Suyang BaiDepartment of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou, China.
Hui WeiDepartment of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou, China.
Yongning ZhouDepartment of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou, China.
Jiangao FanStorr Liver Centre, Westmead Institute for Medical Research, University of Sydney at Westmead Clinical School, Westmead, Australia.
Liang QiaoDepartment of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou, China. liang.qiao@sydney.edu.au.ORCID http://orcid.org/0000-0002-9627-4887
First Hospital of Lanzhou University · CNThe University of Sydney · AUWestmead Institute · AU

Funding

Jiangsu Key Laboratory of Agricultural Meteorology Foundation (CN) CBSKL201718National Natural Science Foundation of China 81570783National Science and Technology Support Program 2015BAI13B07
6 · The paper itself

Abstract

backgroundControlled attenuation parameter (CAP) is a non-invasive method for diagnosing hepatic steatosis. Despite good diagnostic performance, clinical application of CAP is limited due to the influences of covariates. Here, a systematic review on the performance of CAP in the diagnosis and staging of hepatic steatosis in NAFLD patients was performed.

methodsThe sensitivity, specificity, diagnostic odds ratio (DOR) and area under receiver operating characteristics (AUROC) curves of the pooled data for CAP in diagnosing and staging the mild (Stage 1), moderate (Stage 2) and severe (Stage 3) steatosis in NAFLD patients were assessed. The clinical utility of CAP was evaluated by Fagan plot. Heterogeneity was explored using subgroup analysis.

resultsNine studies involving 1297 patients with liver biopsy-proven NAFLD were analyzed. The pooled sensitivity of CAP in detecting mild hepatic steatosis was 87% with a specificity of 91% and a DOR of 84.35. The pooled sensitivity of CAP in detecting moderate hepatic steatosis was 85% with a specificity of 74% and a DOR of 21.28. For severe steatosis, the pooled sensitivity was 76% with a specificity of 58% and a DOR of 4.70. The mean AUROC value for CAP in the diagnosis of mild, moderate, and severe steatosis was 0.96, 0.82 and 0.70, respectively. A subgroup analysis indicated that variation in the geographic regions, cutoffs, age and body mass index (BMI) could be the potential sources of heterogeneity in the diagnosis of moderate to severe steatosis.

conclusionsCAP should be cautiously considered as a non-invasive substitute for liver biopsy in clinical practice.

Indexed as

BiopsyElasticity Imaging TechniquesHumansNon-alcoholic Fatty Liver DiseaseROC CurveSensitivity and SpecificityControlled attenuation parameter (CAP)Hepatic steatosis, diagnostic accuracyNon-alcoholic fatty liver disease (NAFLD)Transient elastography

Identifiers

PMID30961539
PMCPMC6454693
OpenAlexW2943153039

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.